



September 27, 2025

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL
--	---

Sub: Disclosure for change in shareholding in terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulation, 2011

Dear Sir/Madam,

With reference to the aforementioned subject, please find enclosed herewith the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulation, 2011 in respect of disposal / sale of Equity Shares of ANLON HEALTHCARE LIMITED.

You are requested to please take on record and disseminate the same on your respective website.

Thanking You.

Yours Faithfully,

For ANLON HEALTHCARE LIMITED

Rasadia

Punitkumar

Rameshbhai

PUNITKUMAR RASADIA

MANAGING DIRECTOR

DIN: 06696258

Digitally signed by Rasadia Punitkumar Rameshbhai
DN: c=IN, o=Personal, title=4798,
pseudoym=13363440366292472861WAue1dgl1P
1,
2.5.4.20=a003a5c41c134976122ref293c4077137aa
4a1ed74ed223ac0e8dc9264a5a2,
postalCode=360005, st=Gujarat,
serialNumber=9067d666c809e74b4abe895e7d3c8
41c1ee4ee9028483240075802c5a6b96163f3,
cn=Rasadia Punitkumar Rameshbhai
Date: 2025.09.27 12:02:00 +05'30'

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



NEOMILE
ASSET MANAGERS PVT. LTD.

Date: 26th September 2025

To,

The National Stock Exchange of India Ltd.
The Listing Department
Exchange Plaza,
Bandra- Kurla Complex,
Mumbai - 400051
NSE Scrip Code: AHCL

To,

BSE Limited.
Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001
BSE Scrip Code: 544497

To,

Anlon Healthcare Limited
101/102, Silvercoin Complex, Opp. Crystal Mall,
Kalawad Road, Rajkot - 360 005, Gujarat,
India.

Dear Sir/Madam,

Sub: Compliance in terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

With reference to the subject matter, enclosed herewith please find Disclosure in compliance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

You are requested to note that the said sale transactions

Kindly acknowledge receipt of the same.

Thanking you.

For Neomile Asset Managers Private Limited


Rashesh Shah
(Director)

Encl: a/a





NEOMILE

ASSET MANAGERS PVT. LTD.

**Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and
Takeovers) Regulations, 2011**

Name of the Target Company (TC)	Anlon Healthcare Ltd		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Neomile Growth Fund – Series I, Neomile Corporate Advisory Limited		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited (NSE), Bombay Stock Exchanged Ltd (BSE)		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the disposal under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	68,61,261	12.91	12.91
b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	Nil	Nil	Nil
c) Voting rights (VR) otherwise than by shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e) Total (a+b+c+d)	68,61,261	12.91	12.91
Details of acquisition / sale			
a) Shares carrying voting rights acquired/sold	13,32,594	2.51	2.51
b) VRs acquired /sold otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-
d) Shares encumbrance/ invoked/ released by the acquirer	-	-	-
e) Total (a+b+c+/-d)	13,32,594	2.51	2.51
After the acquisition/sale, holding of seller along with PACs of:			
a) Shares carrying voting rights	55,28,667	10.40	10.40
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
e) Total (a+b+c+d)	55,28,667	10.40	10.40



NEOMILE
ASSET MANAGERS PVT. LTD.

Mode of acquisition/sale (e.g. open market /Public issue/ rights issue / preferential allotment / inter-se transfer/encumbrances, etc).	Open Market
Date of acquisition / sale of Shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	Between 19th September 2025 to 24 th September 2025
Equity share capital / total voting capital of the TC before the said acquisition / sale	5,31,51,500
Equity share capital/ total voting capital of the TC after the said acquisition / sale	5,31,51,500
Total diluted share/voting capital of the TC after the said acquisition / sale	5,31,51,500

Part-B***

Name of the Target Company: Anlon Healthcare Ltd

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and / or PACs
Neomile Corporate Advisory Limited	No	
Neomile Growth Fund – Series I	No	

For Neomile Growth Fund – Series I


CA Rashesh Shah
(Director)



Place: Mumbai
Date: 26th September 2025

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.